A Double-blind Randomized Controled Prospective Clinical Trial of Somatostatin in the Prevention of post ERCP Pancreatitis

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-PRC-09000449

Enrollment

Unknown

Registered

2009-06-23

Start date

2008-12-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post endoscopic retrograde cholangiopancreatography pancreatitis

Interventions

Group A:Somatostatin,6 mg, intravenously guttae once before ERCP

Group B:Somatostatin,6 mg, intravenously guttae once after ERCP

Group C:physiological saline

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Male and female aged 18 to 80 years old; 2.Able and willing to perform ERCP in our hospital during Dec.2008 to Dec.2009; 3.The serum-amylase and serum-lipase is normal before ERCP.

Exclusion criteria

Exclusion criteria: 1.Patients with acute pancreatitis or acute episode of chronic pancreatitis; 2.pregnancy or lactation women.; 3.allergy to contrast media and Somatostatin.

Design outcomes

Primary

Measure	Time frame
serum concentration of amylaselipase;Serum lipas;	—

Secondary

Measure	Time frame
biochemical indices of liver and kidney function;Count of blood cell;	—

Countries

China

Contacts

Public ContactWen Li

liwen2000@yahoo.com+86 010 66939377

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026